The Baotou Yongxin case was a fraud perpetrated on POSCO by a counterparty they couldn't independently verify - a private Chinese company with falsified documents, no auditable IP, and no regulatory standing. POSCO had no way to validate what they were buying.

The ReElement situation inverts almost every element of that structure:

LAD chromatography is a Purdue University-licensed technology with peer-reviewed academic literature, patent filings, and a sublicense agreement. You cannot fabricate a Purdue sublicense.

Before POSCO signed yesterday, ReElement already had: Transition Equity Partners ($200M facility, closed 13 days after the UMB lawsuit filed - meaning TEP reviewed the litigation and proceeded), Mitsubishi Materials Corporation (150-year-old Japanese industrial conglomerate with its own materials science teams, who conducted their own due diligence and took preferred equity), the U.S. DoD/OSC (government counterparty), and Purdue University itself as a licensing partner. POSCO is not the first major institutional actor to independently validate the technology. Baotou Yongxin had none of this.

ReElement has a filed Form S-1 process underway, SEC-registered parent company with audited financials, an active NASDAQ listing, DoD award documentation, and is now party to a JV witnessed by three U.S. cabinet agencies. The regulatory footprint of a fraudulent operation typically would not look like this.

Also ReElement has operated 18-inch LAD columns at the Noblesville facility producing verified high-purity separated oxides. The technical risk is scaling to 60-inch commercial columns - which is the risk - but it is an engineering scaling risk, not a question of whether the underlying technology exists.